Page 7 of 8
ACS Medicinal Chemistry Letters
the tumor microenvironment. Semin. Cancer Biol. 2005, 15, 149-
157.
(5) Premzl, A.; Zavasnik-Bergant, V.; Turk, V.; Kos, J.
Intracellular and extracellular cathepsin B facilitate invasion of
MCF-10A neoT cells through reconstituted extracellular matrix
in vitro. Exp. Cell Res. 2003, 283, 206-214.
(21) Schirmeister, T.; Peric, M. Aziridinyl peptides as
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
inhibitors of cysteine proteases: effect of a free carboxylic acid
function on inhibition. Bioorg. Med. Chem. 2000, 8, 1281-1291.
(22) Wieczerzak, E.; Drabik, P.; Łankiewicz, L.; Ołdziej, S.;
Grzonka, Z.; Abrahamson, M.; Grubb, A.; Brömme, D.
Azapeptides structurally based upon inhibitory sites of cystatins
as potent and selective inhibitors of cysteine proteases. J. Med.
Chem. 2002, 45, 4202-4211.
(23) Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.;
Knight, C. G.; Tamai, M.; Hanada, K. L-trans-Epoxysuccinyl-
leucylamido(4-guanidino)butane (E-64) and its analogues as
inhibitors of cysteine proteinases including cathepsins B, H and
L. Biochem. J. 1982, 201, 189-198.
(24) Murata, M.; Miyashita, S.; Yokoo, C.; Tamai, M.; Hanada,
K.; Hatayama, K.; Towatari, T.; Nikawa, T.; Katunuma, N. Novel
epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in
vitro. FEBS Lett. 1991, 280, 307-310.
(25) Schaschke, N.; Assfalg-Machleidt, I.; Machleidt, W.; Turk,
D.; Moroder, L. E-64 analogues as inhibitors of cathepsin B. On
the role of the absolute configuration of the epoxysuccinyl
group. Bioorg. Med. Chem. 1997, 5, 1789-1797.
(26) Schaschke, N.; Assfalg-Machleidt, I.; Machleidt, W.;
Moroder, L. Substrate/propeptide-derived endo-epoxysuccinyl
peptides as highly potent and selective cathepsin B inhibitors.
FEBS Lett. 1998, 421, 80-82.
(27) Turk, D.; Podobnik, M.; Popovic, T.; Katunuma, N.; Bode,
W.; Huber, R.; Turk V. Crystal structure of cathepsin B inhibited
with CA030 at 2.0-A resolution: A basis for the design of specific
epoxysuccinyl inhibitors. Biochemistry 1995, 34, 4791-4797.
(28) Cathers, B. E.; Barrett, C.; Palmer, J. T.; Rydzewski, R. M.
pH Dependence of inhibitors targeting the occluding loop of
cathepsin B. Bioorg. Chem. 2002, 30, 264-275.
(29) Frizler, M.; Lohr, F.; Lülsdorff, M.; Gütschow, M. Facing
the gem-dialkyl effect in enzyme inhibitor design: preparation of
homocycloleucine-based azadipeptide nitriles. Chem. Eur. J.
2011, 17, 11419-11423.
(30) Frizler, M.; Lohr, F.; Furtmann, N.; Kläs, J.; Gütschow, M.
Structural optimization of azadipeptide nitriles strongly
increases association rates and allows the development of
selective cathepsin inhibitors. J. Med. Chem. 2011, 54, 396-400.
(31) Löser, R.; Schilling, K.; Dimmig, E.; Gütschow, M.
Interaction of papain-like cysteine proteases with dipeptide-
derived nitriles. J. Med. Chem. 2005, 48, 7688-7707.
(6) Sosič, I.; Mirković, B.; Arenz, K.; Stefane, B.; Kos, J.; Gobec,
S. Development of new cathepsin B inhibitors: combining
bioisosteric replacements and structure-based design to explore
the structure-activity relationships of nitroxoline derivatives. J.
Med. Chem. 2013, 56, 521-533.
(7) Reiser, J.; Adair, B.; Reinheckel, T. Specialized roles for
cysteine cathepsins in health and disease. J. Clin. Invest. 2010,
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
20, 3421-3431.
8) Nägler, D. K.; Storer, A. C.; Portaro, F. C.; Carmona, E.;
(
Juliano, L.; Ménard, R. Major increase in endopeptidase activity
of human cathepsin B upon removal of occluding loop contacts.
Biochemistry. 1997, 36, 12608-12615.
(9) Illy, C.; Quraishi, O.; Wang, J.; Purisima, E.; Vernet, T.;
Mort, J. S. Role of the occluding loop in cathepsin B activity. J.
Biol. Chem. 1997, 272, 1197-1202.
(10) Schenker, P.; Alfarano, P.; Kolb, P.; Caflisch, A.; Baici A. A
double-headed cathepsin B inhibitor devoid of warhead. Protein
Sci. 2008, 17, 2145-2155.
(11) Musil, D.; Zucic, D.; Turk, D.; Engh, R. A.; Mayr, I.; Huber,
R.; Popovic, T.; Turk, V.; Towatari, T.; Katunuma, N.; Bode, W.
The refined 2.15 A X-ray crystal structure of human liver
cathepsin B: the structural basis for its specificity. EMBO J. 1991,
10, 2321-2330.
(12) Greenspan, P. D.; Clark, K. L.; Tommasi, R. A.; Cowen, S.
D.; McQuire, L. W.; Farley, D. L.; van Duzer, J. H.; Goldberg, R.
L.; Zhou, H.; Du, Z.; Fitt, J. J.; Coppa, D. E.; Fang, Z.; Macchia,
W.; Zhu, L.; Capparelli, M. P.; Goldstein, R.; Wigg, A. M.;
Doughty, J. R.; Bohacek, R. S.; Knap, A. K. Identification of
dipeptidyl nitriles as potent and selective inhibitors of cathepsin
B through structure-based drug design. J. Med. Chem. 2001, 44,
4
524-4534.
(13) Frlan, R.; Gobec, S. Inhibitors of cathepsin B. Curr. Med.
Chem. 2006, 13, 2309-2327.
14) Vicik, R.; Busemann, M.; Baumann, K.; Schirmeister, T.
Inhibitors of cysteine proteases. Curr. Top. Med. Chem. 2006, 6,
31-353.
15) Borišek, J.; Vizovišek, M.; Sosnowski, P.; Turk, B.; Turk,
(
3
(
D.; Mohar, B.; Novič, M. Development of N-(functionalized
benzoyl)-homocycloleucyl-glycinonitriles as potent cathepsin K
inhibitors. J. Med. Chem. 2015, 58, 6928-6937.
(16) Santos, M. M.; Moreira, R. Michael acceptors as cysteine
protease inhibitors. Mini Rev. Med. Chem. 2007, 7, 1040-1050.
(32) Schmitz, J.; Furtmann, N.; Ponert, M.; Frizler, M.; Löser,
R.; Bartz, U.; Bajorath, J.; Gütschow, M. Active site mapping of
human cathepsin
F
with dipeptide nitrile inhibitors.
ChemMedChem. 2015, 10, 1365-1377.
(33) Pedersen, D. S.; Abell, A. 1,2,3-Triazoles in
peptidomimetic chemistry. Eur. J. Org. Chem. 2011, 2399-2411.
(34) Copeland, R. A. Conformational adaptation in drug-target
interactions and residence time. Future Med. Chem. 2011, 3, 1491-
501.
(17) Ettari, R.; Pinto, A.; Tamborini, L.; Angelo, I. C.; Grasso,
S.; Zappalà, M.; Capodicasa, N.; Yzeiraj, L.; Gruber, E.; Aminake,
M. N.; Pradel, G.; Schirmeister, T.; De Micheli, C.; Conti, P.
Synthesis and biological evaluation of papain-family cathepsin L-
like cysteine protease inhibitors containing a 1,4-benzodiazepine
scaffold as antiprotozoal agents. ChemMedChem 2014, 9, 1817-
1825.
(18) Mirković, B.; Renko, M.; Turk, S.; Sosič, I.; Jevnikar, Z.;
Obermajer, N.; Turk, D.; Gobec, S.; Kos, J. Novel mechanism of
cathepsin B inhibition by antibiotic nitroxoline and related
compounds. ChemMedChem 2011, 6, 1351-1356.
(
19) Mirković, B.; Sosič, I.; Gobec, S.; Kos, J. Redox-based
inactivation of cysteine cathepsins by compounds containing the
-aminophenol moiety. PLoS One 2011, 6, e27197.
20) Leung-Toung, R.; Wodzinska, J.; Li, W.; Lowrie, J.;
4
(
Kukreja, R.; Desilets, D.; Karimian, K.; Tam, T. F. 1,2,4-
thiadiazole: a novel Cathepsin B inhibitor. Bioorg. Med. Chem.
2003, 11, 5529-5537.
ACS Paragon Plus Environment